CA24463V1013
© Newsfile
10.12.2025
DTC
LISTED
CSE
Defence Therapeutics Announces AGM Results and Provides Corporate Updates
News Preview
Montreal, Quebec--(Newsfile Corp. - December 10, 2025) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a biotechnology company advancing a proprietary intracellular delivery platform that enables more potent, safer, and more effective antibody-based and radiotherapeutic treatments, is pleased to announ...
Themefolio
Profiler
Peergroup
© Newsfile
04.12.2025
DTC
LISTED
CSE
Defence Therapeutics Announces Formation of Scientific Advisory Board to Guide Advancement of Accum-Enhanced Antibody Drug Conjugate Programs
News Preview
Montreal, Quebec--(Newsfile Corp. - December 4, 2025) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a biotechnology company advancing a proprietary intracellular delivery platform that enables more potent, safer, and more effective antibody-based and radiotherapeutic treatments, is pleased...
Themefolio
Profiler
Peergroup
© Newsfile
22.11.2025
DTC
LISTED
CSE
Defence Therapeutics Announces Convertible Debenture Conversion
News Preview
Montreal, Quebec--(Newsfile Corp. - November 21, 2025) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a leading biotechnology company pioneering next-generation antibody-drug conjugate ("ADC"), announces that the holders of the Corporation's 8% convertible debentures issued on November 16, 2024 (...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© Newsfile
19.11.2025
DTC
LISTED
CSE
Defence Therapeutics to Build ADC Drug Delivery Powerhouse Using Its Proprietary Accum Technology
News Preview
Montreal, Quebec--(Newsfile Corp. - November 19, 2025) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a leading biotechnology company pioneering next-generation antibody-drug conjugate ("ADC"), is pleased to announce a major step forward in the fight against cancer that goes beyond the ADCs...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© Newsfile
06.11.2025
DTC
LISTED
CSE
Defence Announces Successful Presentation at the World ADC Conference in San Diego and Plans to Expand Evaluation of Accum in Commercial and Pipeline ADCs
News Preview
Montreal, Quebec--(Newsfile Corp. - November 6, 2025) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a leading biotechnology company pioneering next-generation antibody-drug conjugate ("ADC"), is pleased to announce the successful presentation of new data on its proprietary Accum® platform at the...
Themefolio
Profiler
Peergroup
© Newsfile
04.11.2025
DTC
LISTED
CSE
Defence Therapeutics Demonstrates Strong Preclinical in Vivo Efficacy Results Evaluating Accum-Kadcyla in Breast Cancer Models
News Preview
Montreal, Quebec--(Newsfile Corp. - November 4, 2025) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a leading biotechnology company specialized in drug delivery technologies, is pleased to announce and to present today at the World ADC Conference in San Diego, USA, highly encouraging results from it...
Themefolio
Profiler
Peergroup
© Newsfile
23.10.2025
DTC
LISTED
CSE
Defence to Present New Scientific Data on Its ADC-Enhancing Accum Technology at the World ADC Conference in San Diego, USA, November 4-5, 2025
News Preview
Montreal, Quebec--(Newsfile Corp. - October 23, 2025) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a leading biotechnology company specialized in drug delivery technologies, is pleased to announce that it will present new scientific data highlighting the performance of its Accum® technolo...
Themefolio
Profiler
Peergroup
© Newsfile
06.10.2025
DTC
LISTED
CSE
Defence Therapeutics to Attend CPHI Worldwide in Frankfurt, October 28-30, 2025
News Preview
Montreal, Quebec--(Newsfile Corp. - October 6, 2025) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a leading biotechnology company specialized in drug delivery technologies, is pleased to announce its participation at CPHI Worldwide 2025, taking place in Frankfurt, Germany from October 28-30, 20...
Themefolio
Profiler
Peergroup
© Newsfile
02.10.2025
DTC
LISTED
CSE
Defence Therapeutics Appoints Dr. Mark Lambermon as Head of Quality and Operations
News Preview
Montreal, Quebec--(Newsfile Corp. - October 2, 2025) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a leading biotechnology company specialized in drug delivery technologies, is pleased to announce the appointment of Mark Lambermon, PhD, as Head of Quality and Operations. Dr. Lambermon brings ove...
Themefolio
Profiler
Peergroup
© Newsfile
23.09.2025
DTC
LISTED
CSE
Defence's Director, Strategy & Business Advisor Dr. Amie Phinney Discusses the Accum Platform on Money Talk Radio with Ellis Martin
News Preview
Montreal, Quebec--(Newsfile Corp. - September 23, 2025) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a leading biotechnology company specialized in drug delivery technologies, is pleased to share the interview of Dr. Amie Phinney, Defence's director, strategy & business advisor, with Ellis Marti...
Themefolio
Profiler
Peergroup
© Newsfile
16.09.2025
DTC
LISTED
CSE
Defence Therapeutics Appoints Dr. Amie Phinney as Director
News Preview
Montreal, Quebec--(Newsfile Corp. - September 16, 2025) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a leading biotechnology company specialized in drug delivery technologies, is pleased to announce the appointment of Dr. Amie Phinney, PhD, MBA to its Board of Directors, effective immediately.D...
Themefolio
Profiler
Peergroup
© Newsfile
15.09.2025
DTC
LISTED
CSE
Defence Therapeutics Completes Fully Subscribed Debenture Units Financing of $2,000,000
News Preview
Montreal, Quebec--(Newsfile Corp. - September 15, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a leading biotechnology company specialized in drug delivery technologies, is pleased to announce the closing of its previously announced non-brokered private placement of debenture units (...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© Newsfile
02.09.2025
DTC
LISTED
CSE
Defence Therapeutics Engages Dr. Amie Phinney as Strategy & Business Advisor to Guide Next Phase of Growth
News Preview
Montreal, Quebec--(Newsfile Corp. - September 2, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a leading biotechnology company specialized in drug delivery technologies, is pleased to announce the engagement of Amie Phinney, PhD, MBA as the Strategy & Business Advisor, effective immediately...
Themefolio
Profiler
Peergroup
© Newsfile
23.08.2025
DTC
LISTED
CSE
Defence Therapeutics Announces Debenture Units Financing
News Preview
Montreal, Quebec--(Newsfile Corp. - August 22, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a leading biotechnology company specialized in drug delivery technologies, is pleased to announce a non-brokered private placement of debenture units (the "Units") at a price of $1,000 per Unit for aggr...
Themefolio
Profiler
Peergroup
© Newsfile
14.07.2025
DTC
LISTED
CSE
Defence's Accum Technology with ADC and Radiopharmaceutical Programs Target Cancer
News Preview
Montreal, Quebec--(Newsfile Corp. - July 14, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a leading biotechnology company specializing in drug delivery technologies, is pleased to announce that its highly impactful programs on ADC and Radiopharma programs, which includes collaboratio...
Themefolio
Profiler
Peergroup
© Newsfile
09.06.2025
DTC
LISTED
CSE
Defence Therapeutics Receives USPTO Allowance for Patent Application Covering Next-Gen ADC Technology
News Preview
Montreal, Quebec--(Newsfile Corp. - June 9, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a leading biotechnology company specializing in drug delivery technologies, is pleased to announce that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for...
Themefolio
Profiler
Peergroup
© Newsfile
02.06.2025
DTC
LISTED
CSE
Defence Therapeutics Opens U.S. Laboratory in Boston-Cambridge Biotech Hub
News Preview
Montreal, Quebec--(Newsfile Corp. - June 2, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a leading biotechnology company specializing in advanced endosomal escape technologies, is pleased to announce the opening of its first U.S. laboratory in the Boston-Cambridge area. This strate...
Themefolio
Profiler
Peergroup
© Newsfile
28.05.2025
DTC
LISTED
CSE
Defence Therapeutics to Attend Bio International Convention in Boston, June 2025
News Preview
Montreal, Quebec--(Newsfile Corp. - May 28, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing advanced cancer therapeutics and drug delivery technologies, is pleased to announce that its Chief Executive Officer and Chief Operating Officer will be atte...
Themefolio
Profiler
Peergroup
© Newsfile
08.04.2025
DTC
LISTED
CSE
Defence Launches Accum Combined with Actinium-225 to Increase Efficacy and Safety of Radio-Immunoconjugate Cancer Therapies
News Preview
Montreal, Quebec--(Newsfile Corp. - April 8, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing advanced cancer therapeutics and drug delivery technologies, is pleased to announce a collaboration with the Canadian Nuclear Laboratories ("CNL"). CNL...
Themefolio
Profiler
Peergroup
© Newsfile
26.03.2025
DTC
LISTED
CSE
Defence Announces US Molecular and Antibody Research Expert Dr. Elias Theodorou Joins Defence's Management Team as Chief Operating Officer
News Preview
Montreal, Quebec--(Newsfile Corp. - March 26, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing radiopharmaceuticals and ADC products using its proprietary platform and drug delivery technologies in addition to novel immune-oncology vaccines, is plea...
Themefolio
Profiler
Peergroup
© Newsfile
01.02.2025
DTC
LISTED
CSE
Defence Closes Second Tranche of Fully Subscribed Financing Totaling $4.2 Million
News Preview
Montreal, Quebec--(Newsfile Corp. - January 31, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing radiopharmaceuticals and ADC products using its proprietary platform and drug delivery technologies in addition to novel immune-oncology vaccines, is ple...
Themefolio
Profiler
Peergroup
© Newsfile
10.01.2025
DTC
LISTED
CSE
Defence to Connect with Industry Leaders and Potential Partners During the JP Morgan Healthcare Conference in San Francisco. Plans to Expand the Next Generation of Radio-Immuno Conjugates in 2025
News Preview
Montreal, Quebec--(Newsfile Corp. - January 10, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company") a Canadian biopharmaceutical company developing radiopharmaceuticals and ADC products using its proprietary platform and drug delivery technologies in addition to novel immune-oncology vaccines, is plea...
Themefolio
Profiler
Peergroup
© Newsfile
06.01.2025
DTC
LISTED
CSE
Defence Fortifies Patent Portfolio
News Preview
Vancouver, British Columbia--(Newsfile Corp. - January 6, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing radiopharmaceuticals and ADC products using its proprietary platform and drug delivery technologies in addition to novel immune-oncology vaccin...
Themefolio
Profiler
Peergroup
© Newsfile
31.12.2024
DTC
LISTED
CSE
Defence Arranges Financing
News Preview
Vancouver, British Columbia--(Newsfile Corp. - December 31, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing radiopharmaceuticals and ADC products using its proprietary platform and drug delivery technologies in addition to novel immune-oncology vacc...
Themefolio
Profiler
Peergroup
© Newsfile
20.12.2024
DTC
LISTED
CSE
Defence Announces Molecular and Antibody Research Expert Dr. Elias Theodorou Joins Its Board of Directors
News Preview
Vancouver, British Columbia--(Newsfile Corp. - December 20, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing radiopharmaceuticals and ADC products using its proprietary platform and drug delivery technologies in addition to novel immune-oncology...
Themefolio
Profiler
Peergroup
© Newsfile
03.12.2024
DTC
LISTED
CSE
Defence Provides Update on Delivery of AGSM Proxy Materials
News Preview
Vancouver, British Columbia--(Newsfile Corp. - December 2, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing radiopharmaceuticals and ADC products using its proprietary platform and drug delivery technologies in addition to novel immune-oncology vacci...
Themefolio
Profiler
Peergroup
© Newsfile
30.11.2024
DTC
LISTED
CSE
Defence's Proprietary Accum Technology Ready to License to Companies Developing Antibody Drug Conjugates (ADC)
News Preview
Vancouver, British Columbia--(Newsfile Corp. - November 29, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing radiopharmaceuticals and ADC products using its proprietary platform and drug delivery technologies in addition to novel immune-oncology vac...
Themefolio
Profiler
Peergroup
© Newsfile
25.11.2024
DTC
LISTED
CSE
Defence Announces Dr. Maxime Parisotto as CSO, Director of Science and Business Development
News Preview
Vancouver, British Columbia--(Newsfile Corp. - November 25, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing radiopharmaceuticals and ADC products using its proprietary platform and drug delivery technologies in addition to novel immune-oncology vacc...
Themefolio
Profiler
Peergroup
© Newsfile
23.11.2024
DTC
LISTED
CSE
Defence Announces Closing of Securities for Debenture Financing
News Preview
Vancouver, British Columbia--(Newsfile Corp. - November 22, 2024) - DEFENCE THERAPEUTICS INC. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing radiopharmaceuticals and ADC products using its proprietary platform and drug delivery technologies in addition to novel immune-oncology vacc...
Themefolio
Profiler
Peergroup
© Newsfile
15.11.2024
DTC
LISTED
CSE
Defence Therapeutics Announces Securities for Debenture Financing
News Preview
Vancouver, British Columbia--(Newsfile Corp. - November 14, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing radiopharmaceuticals and ADC products using its proprietary platform and drug delivery technologies in addition to novel immune-oncology vacc...
Themefolio
Profiler
Peergroup
© Newsfile
13.11.2024
DTC
LISTED
CSE
Defence Announces Radiopharmaceutical Expert Svetlana Selivanova Joins Board of Directors
News Preview
Vancouver, British Columbia--(Newsfile Corp. - November 13, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing radiopharmaceuticals and ADC products using its proprietary platform and drug delivery technologies in addition to novel immune-oncology vacc...
Themefolio
Profiler
Peergroup
© Newsfile
05.11.2024
DTC
LISTED
CSE
Defence Announces Extension of Private Placement, Continues Development of Its Radiopharmaceuticals and ADC Programs
News Preview
Vancouver, British Columbia--(Newsfile Corp. - November 4, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing radiopharmaceuticals and ADC products using its proprietary platform and drug delivery technologies in addition to novel immune-oncology...
Themefolio
Profiler
Peergroup
© Newsfile
30.10.2024
DTC
LISTED
CSE
Defence Therapeutics Completes 1st Tranche of Financing
News Preview
Vancouver, British Columbia--(Newsfile Corp. - October 30, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing radiopharmaceuticals and novel immune-oncology vaccines and drug delivery technologies, is pleased to announce the closing of the 1st tra...
Themefolio
Profiler
Peergroup
© Newsfile
27.09.2024
DTC
LISTED
CSE
Defence's Corporate Updates, Arranges Financing
News Preview
Vancouver, British Columbia--(Newsfile Corp. - September 27, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing radiopharmaceuticals and novel immune-oncology vaccines and drug delivery technologies, is pleased to give a corporate update and to announc...
Themefolio
Profiler
Peergroup
© Newsfile
31.08.2024
DTC
LISTED
CSE
Defence Appoints New Interim Chief Executive Officer
News Preview
Vancouver, British Columbia--(Newsfile Corp. - August 30, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), announces that Kwin Grauer has been appointed interim Chief Executive Officer replacing Sébastien Plouffe as President and Chief Executive Officer. This change comes as the Company move...
Themefolio
Profiler
Peergroup
© EQS Newswire
19.08.2024
DTC
LISTED
CSE
DEFENCE UNTERSUCHT DIE ANWENDUNG DER ACCUM®- HYDROGELTECHNOLOGIE ZUM TRANSPORT VON GLP-1 ZWECKS VERBESSERUNG DER WIRKSAMKEIT DER BEHANDLUNG VON DIABETES UND ZUM ERZIELEN EINES GEWICHTSVERLUSTS
News Preview
_________________________________________________________________
CSE: DTC Börse Frankfurt: DTC USOTC: DTCFF PRESSEMITTEILUNG
DEFENCE UNTERSUCHT DIE ANWENDUNG DER ACCUM®- HYDROGELTECHNOLOGIE ZUM TRANSPORT VON GLP-1 ZWECKS VERBESSERUNG DER WIRKSAMKEIT DER BEHANDLUNG VON DIABETES UND ZUM ERZIELEN EINES GEWICHTSVERLUSTS
Vancouver, Br......
Themefolio
Profiler
Peergroup
© EQS Newswire
19.08.2024
DTC
LISTED
CSE
DEFENCE INVESTIGATES THE APPLICATION OF THE ACCUM® HYDROGEL TECHNOLOGY TO DELIVER GLP-1 IN ORDER TO INCREASE THE TREATMENT EFFICACY OF DIABETES AND WEIGHT LOSS
News Preview
_________________________________________________________________
CSE: DTC FSE: DTC USOTC: DTCFF PRESS RELEASE
DEFENCE INVESTIGATES THE APPLICATION OF THE ACCUM® HYDROGEL TECHNOLOGY TO DELIVER GLP-1 IN ORDER TO INCREASE THE TREATMENT EFFICACY OF DIABETES AND WEIGHT LOSS
Vancouver, BC, Canada, August 19th, 2024 - Defence Therapeutics I......
Themefolio
Profiler
Peergroup
© Newsfile
19.08.2024
DTC
LISTED
CSE
Defence Investigates the Application of the Accum Hydrogel Technology to Deliver GLP-1 in Order to Increase the Treatment Efficacy of Diabetes and Weight Loss
News Preview
Vancouver, British Columbia--(Newsfile Corp. - August 19, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing novel immune-oncology vaccines and drug delivery technologies, is pleased to announce a project consisting of investigating the potential benef...
Themefolio
Profiler
Peergroup
© EQS Newswire
13.08.2024
DTC
LISTED
CSE
KOOPERATIONSVEREINBARUNG VON DEFENCE THERAPEUTICS MIT ORANO ZUR ENTWICKLUNG DER NÄCHSTEN GENERATION DER GEZIELTEN RADIOIMMUNTHERAPIE FÜR FORTSCHRITTE BEI DER KREBSBEKÄMPFUNG
News Preview
_________________________________________________________________
CSE: DTC Börse Frankfurt: DTC USOTC: DTCFF PRESSEMITTEILUNG
KOOPERATIONSVEREINBARUNG VON DEFENCE THERAPEUTICS MIT ORANO ZUR ENTWICKLUNG DER NÄCHSTEN GENERATION DER GEZIELTEN RADIOIMMUNTHERAPIE FÜR FORTSCHRITTE BEI DER KREBSBEKÄMPFUNG
Vancouver, Britisch Columbia, Ka......
Themefolio
Profiler
Peergroup
© Newsfile
13.08.2024
DTC
LISTED
CSE
Defence Therapeutics Collaboration Agreement with Orano to Develop the Next Generation of Targeted Radio-Immunotherapy for Cancer Advances
News Preview
Vancouver, British Columbia--(Newsfile Corp. - August 13, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing novel immune-oncology vaccines and drug delivery technologies, is please to give an update on its Orano Support SAS partnership in the radiopha...
Themefolio
Profiler
Peergroup
© EQS Newswire
13.08.2024
DTC
LISTED
CSE
DEFENCE THERAPEUTICS COLLABORATION AGREEMENT WITH ORANO TO DEVELOP THE NEXT GENERATION OF TARGETED RADIO-IMMUNOTHERAPY FOR CANCER ADVANCES
News Preview
_________________________________________________________________
CSE: DTC FSE: DTC USOTC: DTCFF PRESS RELEASE
DEFENCE THERAPEUTICS COLLABORATION AGREEMENT WITH ORANO TO DEVELOP THE NEXT GENERATION OF TARGETED RADIO-IMMUNOTHERAPY FOR CANCER ADVANCES
Vancouver, BC, Canada, August 13th, 2024 - Defence Therapeutics Inc. (“Defence” or ......
Themefolio
Profiler
Peergroup
© EQS Newswire
24.07.2024
DTC
LISTED
CSE
DEFENCE THERAPEUTICS ERHÄLT UNTERSTÜTZUNG DURCH DAS CNRI-H-PROJEKT VON CANADIAN NUCLEAR LABORATORIES ZUR BESCHLEUNIGUNG DER ENTWICKLUNG SEINES RADIOIMMUNOKONJUGAT-PROGRAMMS
News Preview
_________________________________________________________________
CSE: DTC Börse Frankfurt: DTC USOTC: DTCFF PRESSEMITTEILUNG
DEFENCE THERAPEUTICS ERHÄLT UNTERSTÜTZUNG DURCH DAS CNRI-H-PROJEKT VON CANADIAN NUCLEAR LABORATORIES ZUR BESCHLEUNIGUNG DER ENTWICKLUNG SEINES RADIOIMMUNOKONJUGAT-PROGRAMMS
Vancouver, Britisch Columbia, Kana......
Themefolio
Profiler
Peergroup
© Newsfile
24.07.2024
DTC
LISTED
CSE
Defence Therapeutics Granted CNRI-H from the Canadian Nuclear Laboratories to Accelerate the Development of Its Radio-Immuno-Conjugates Program
News Preview
Vancouver, British Columbia--(Newsfile Corp. - July 24, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing novel immune-oncology vaccines and drug delivery technologies, is pleased to announce that its Canadian Nuclear Research Initiative Health ("CNRI...
Themefolio
Profiler
Peergroup
© EQS Newswire
24.07.2024
DTC
LISTED
CSE
DEFENCE THERAPEUTICS GRANTED CNRI-H FROM THE CANADIAN NUCLEAR LABORATORIES TO ACCELERATE THE DEVELOPMENT OF ITS RADIO-IMMUNO-CONJUGATES PROGRAM
News Preview
_________________________________________________________________
CSE: DTC FSE: DTC USOTC: DTCFF PRESS RELEASE
DEFENCE THERAPEUTICS GRANTED CNRI-H FROM THE CANADIAN NUCLEAR LABORATORIES TO ACCELERATE THE DEVELOPMENT OF ITS RADIO-IMMUNO-CONJUGATES PROGRAM
Vancouver, BC, Canada, July 24th, 2024 - Defence Therapeutics Inc. (“Defence” o......
Themefolio
Profiler
Peergroup
© EQS Newswire
08.07.2024
DTC
LISTED
CSE
DEFENCE ERHÄLT ‚NO OBJECTION LETTER’ VON DER KANADISCHEN GESUNDHEITSBEHÖRDE HEALTH CANADA FÜR SEINE PHASE I-STUDIE MIT ACCUM-002 (ACCUTOX) ALS MOLEKÜL ZUR KREBSBEKÄMPFUNG BEI PATIENTEN MIT MELANOMEN
News Preview
CSE: DTC Börse Frankfurt: DTC USOTC: DTCFF PRESSEMITTEILUNG
DEFENCE ERHÄLT ‚NO OBJECTION LETTER’ VON DER KANADISCHEN GESUNDHEITSBEHÖRDE HEALTH CANADA FÜR SEINE PHASE I-STUDIE MIT ACCUM-002 (ACCUTOX) ALS MOLEKÜL ZUR KREBSBEKÄMPFUNG BEI PATIENTEN MIT MELANOMEN
Vancouver, Britisch Columbia, Kanada, den 8. Juli 2024 – Defence Therapeuti......
Themefolio
Profiler
Peergroup
© Newsfile
08.07.2024
DTC
LISTED
CSE
Defence Receives No Objection Letter from Health Canada for Phase I Trial of Its ACCUM-002 (AccuTOX) as an Anti-Cancer Molecule in Patients with Melanoma
News Preview
Vancouver, British Columbia--(Newsfile Corp. - July 8, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing novel immune-oncology vaccines and drug delivery technologies, is pleased to announce that it received a No Objection Letter ("NOL") from Health C...
Themefolio
Profiler
Peergroup
© EQS Newswire
08.07.2024
DTC
LISTED
CSE
DEFENCE RECEIVES NO OBJECTION LETTER FROM HEALTH CANADA FOR PHASE I TRIAL OF ITS ACCUM-002 (ACCUTOX) AS AN ANTI-CANCER MOLECULE IN PATIENTS WITH MELANOMA
News Preview
_________________________________________________________________
CSE: DTC FSE: DTC USOTC: DTCFF PRESS RELEASE
DEFENCE RECEIVES NO OBJECTION LETTER FROM HEALTH CANADA FOR PHASE I TRIAL OF ITS ACCUM-002 (ACCUTOX) AS AN ANTI-CANCER MOLECULE IN PATIENTS WITH MELANOMA
Vancouver, BC, Canada, July 8th, 2024 - Defence Therapeutics Inc. (“......
Themefolio
Profiler
Peergroup
© EQS Newswire
01.07.2024
DTC
LISTED
CSE
ACCUTOX VON DEFENCE VERSTÄRKT DIE WIRKUNG VON IMMUNCHECKPOINTINHIBITOREN UND SCHAFFT SO SYNERGIEEFFEKTE
News Preview
CSE: DTC Börse Frankfurt: DTC USOTC: DTCFF PRESSEMITTEILUNG
ACCUTOX VON DEFENCE VERSTÄRKT DIE WIRKUNG VON IMMUNCHECKPOINTINHIBITOREN UND SCHAFFT SO SYNERGIEEFFEKTE
Vancouver, Britisch Columbia, Kanada, den 28. Juni 2024 – Defence Therapeutics Inc. („Defence“ oder das „Unternehmen“), (CSE: DTC, OTCQB: DTCFF, Börse Frankfurt: DTC), ein kan......
Themefolio
Profiler
Peergroup
© EQS Newswire
01.07.2024
DTC
LISTED
CSE
DEFENCE’S ACCUTOX BOOSTS AND SYNERGIZES WITH IMMUNE CHECKPOINT INHIBITORS
News Preview
_________________________________________________________________
CSE: DTC FSE: DTC USOTC: DTCFF PRESS RELEASE
DEFENCE’S ACCUTOX BOOSTS AND SYNERGIZES WITH IMMUNE CHECKPOINT INHIBITORS
Vancouver, BC, Canada, June 28th, 2024 - Defence Therapeutics Inc. (“Defence” or the “Company”), (CSE: DTC, OTCQB: DTCFF, FSE: DTC), a Canadian biop......
Themefolio
Profiler
Peergroup
© Newsfile
28.06.2024
DTC
LISTED
CSE
Defence's AccuTOX Boosts and Synergizes with Immune Checkpoint Inhibitors
News Preview
Vancouver, British Columbia--(Newsfile Corp. - June 28, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing novel immune-oncology vaccines and drug delivery technologies, is please to announce that Defence's Accum-002TM ("AccuTOX®") has different m...
Themefolio
Profiler
Peergroup
© EQS Newswire
25.06.2024
DTC
LISTED
CSE
DER ARM-X-IMPFSTOFF ZUR KREBSBEKÄMPFUNG VON DEFENCE HEMMT DAS WACHSTUM VON BESTEHENDEM EIERSTOCKKREBS UND FÜHRT BEI BEHANDELTEN TIEREN ZU VOLLSTÄNDIGEN REAKTIONEN
News Preview
_________________________________________________________________
CSE: DTC Börse Frankfurt: DTC USOTC: DTCFF PRESSEMITTEILUNG
DER ARM-X-IMPFSTOFF ZUR KREBSBEKÄMPFUNG VON DEFENCE HEMMT DAS WACHSTUM VON BESTEHENDEM EIERSTOCKKREBS UND FÜHRT BEI BEHANDELTEN TIEREN ZU VOLLSTÄNDIGEN REAKTIONEN
Vancouver, Britisch Columbia, Kanad......
Themefolio
Profiler
Peergroup
© Newsfile
25.06.2024
DTC
LISTED
CSE
Defence's ARM-X Anti-Cancer Vaccine Inhibits Growth of Pre-Established Ovarian Cancer Resulting in Complete Responses in Treated Animals
News Preview
Vancouver, British Columbia--(Newsfile Corp. - June 25, 2024) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing novel immune-oncology vaccines and drug delivery technologies, is pleased to announce that its second-generation ARM-X anti-cancer vaccine is the...
Themefolio
Profiler
Peergroup
© EQS Newswire
25.06.2024
DTC
LISTED
CSE
DEFENCE’S ARM-X ANTI-CANCER VACCINE INHIBITS GROWTH OF PRE-ESTABLISHED OVARIAN CANCER RESULTING IN COMPLETE RESPONSES IN TREATED ANIMALS
News Preview
CSE: DTC FSE: DTC USOTC: DTCFF PRESS RELEASE
Vancouver, BC, Canada, June 25th, 2024 - Defence Therapeutics Inc. (“Defence” or the “Company”), a Canadian biopharmaceutical company developing novel immune-oncology vaccines and drug delivery technologies, is pleased to announce that its second-generation ARM-X anti-cancer vaccine is therap......
Themefolio
Profiler
Peergroup
© EQS Newswire
25.06.2024
DTC
LISTED
CSE
DEFENCE’S ARM-X ANTI-CANCER VACCINE INHIBITS GROWTH OF PRE-ESTABLISHED OVARIAN CANCER RESULTING IN COMPLETE RESPONSES IN TREATED ANIMALS
News Preview
CSE: DTC FSE: DTC USOTC: DTCFF PRESS RELEASE
Vancouver, BC, Canada, June 25th, 2024 - Defence Therapeutics Inc. (“Defence” or the “Company”), a Canadian biopharmaceutical company developing novel immune-oncology vaccines and drug delivery technologies, is pleased to announce that its second-generation ARM-X anti-cancer vaccine is therap......
Themefolio
Profiler
Peergroup
© EQS Newswire
17.06.2024
DTC
LISTED
CSE
DER WISSENSCHAFTLICHE LEITER VON DEFENCE, DR. MOUTIH RAFEI, SPRICHT AUF MONEY TALK RADIO MIT ELLIS MARTIN ÜBER DIE ACCUM-PLATFORM ZUR KREBSBEKÄMPFUNG
News Preview
_________________________________________________________________
CSE: DTC Börse Frankfurt: DTC USOTC: DTCFF PRESSEMITTEILUNG
DER WISSENSCHAFTLICHE LEITER VON DEFENCE, DR. MOUTIH RAFEI, SPRICHT AUF MONEY TALK RADIO MIT ELLIS MARTIN ÜBER DIE ACCUM-PLATFORM ZUR KREBSBEKÄMPFUNG
Vancouver, British Columbia, Kanada, den 17. Juni 2024......
Themefolio
Profiler
Peergroup
© Newsfile
17.06.2024
DTC
LISTED
CSE
Defence's Chief Scientific Officer Dr. Moutih Rafei Discusses the Accum Platform for Cancer Treatments on Money Talk Radio with Ellis Martin
News Preview
Vancouver, British Columbia--(Newsfile Corp. - June 17, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing novel immune-oncology vaccines and drug delivery technologies, is please to share the interview of Dr. Moutih Rafei, Defence's Chief Scientific O...
Themefolio
Profiler
Peergroup
© EQS Newswire
17.06.2024
DTC
LISTED
CSE
DEFENCE’S CHIEF SCIENTIFIC OFFICER DR. MOUTIH RAFEI DISCUSSES THE ACCUM PLATFORM FOR CANCER TREATMENTS ON MONEY TALK RADIO WITH ELLIS MARTIN
News Preview
_________________________________________________________________
CSE: DTC FSE: DTC USOTC: DTCFF PRESS RELEASE
DEFENCE’S CHIEF SCIENTIFIC OFFICER DR. MOUTIH RAFEI DISCUSSES THE ACCUM PLATFORM FOR CANCER TREATMENTS ON MONEY TALK RADIO WITH ELLIS MARTIN
Vancouver, BC, Canada, June 17th, 2024 - Defence Therapeutics Inc. (“Defence” or ......
Themefolio
Profiler
Peergroup
© EQS Newswire
10.06.2024
DTC
LISTED
CSE
DEFENCE NIMMT AN JAHRESTAGUNG DER ‚SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING‘ IN TORONTO AM 11. JUNI 2024 TEIL
News Preview
CSE: DTC Börse Frankfurt: DTC USOTC: DTCFF PRESSEMITTEILUNG
DEFENCE NIMMT AN JAHRESTAGUNG DER ‚SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING‘ IN TORONTO AM 11. JUNI 2024 TEIL
Vancouver, British Columbia, Kanada, den 10. Juni 2024 - Defence Therapeutics Inc. („Defence“ oder das „Unternehmen“) (CSE: DTC, OTCQB: DTCFF, Börse Frankfurt: ......
Themefolio
Profiler
Peergroup
© Newsfile
10.06.2024
DTC
LISTED
CSE
Defence to Participate in 2024 Society of Nuclear Medicine and Molecular Imaging Annual Meeting in Toronto on June 11, 2024
News Preview
Vancouver, British Columbia--(Newsfile Corp. - June 10, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC), ("Defence" or the "Company"), a Canadian biopharmaceutical company developing novel immune-oncology vaccines and drug delivery technologies, is please to announce its participation to the Society of Nuclear and Molecular I...
Themefolio
Profiler
Peergroup
© EQS Newswire
10.06.2024
DTC
LISTED
CSE
DEFENCE TO PARTICIPATE TO 2024 SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING ANNUAL MEETING IN TORONTO ON JUNE 11, 2024
News Preview
_________________________________________________________________
CSE: DTC FSE: DTC USOTC: DTCFF PRESS RELEASE
DEFENCE TO PARTICIPATE TO 2024 SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING ANNUAL MEETING IN TORONTO ON JUNE 11, 2024
Vancouver, BC, Canada, June 10th, 2024 - Defence Therapeutics Inc. (“Defence” or the “Company”), (......
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
